Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-11-27

FDA Approved: DIFLUPREDNATE OPHTHALMIC — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for difluprednate ophthalmic from Sandoz Inc, authorizing changes to its labeling following submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Difluprednate ophthalmic (Difluprednate)

Snippet

SUPPL AP for DIFLUPREDNATE OPHTHALMIC (DIFLUPREDNATE OPHTHALMIC)